Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Other Pulmonary Disorders01:17

Other Pulmonary Disorders

899
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
899
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

334
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
334
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

3.0K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
3.0K
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

314
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
314
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

2.9K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.9K
Pleural Disorders: Types and Brief Description01:30

Pleural Disorders: Types and Brief Description

288
The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:
288

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mesalazine-induced lung injury with severe respiratory failure successfully treated with steroids and non-invasive positive pressure ventilation.

Respiratory medicine case reports·2020
Same author

Catheter-Free Arrhythmia Ablation Using Scanned Proton Beams: Electrophysiologic Outcomes, Biophysics, and Characterization of Lesion Formation in a Porcine Model.

Circulation. Arrhythmia and electrophysiology·2020
Same author

Friction behavior of high-density poly(2-methacryloyloxyethyl phosphorylcholine) brush in aqueous media.

Soft matter·2020
Same author

Executive summary of clinical practice guide on fracture risk in lifestyle diseases.

Journal of bone and mineral metabolism·2020
Same author

Geochemical distribution of heavy metal elements and potential ecological risk assessment of Matsushima Bay sediments during 2012-2016.

The Science of the total environment·2020
Same author

Vasopressin escape and memory impairment in a model of chronic syndrome of inappropriate secretion of antidiuretic hormone in mice.

Endocrine journal·2020
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

Related Experiment Video

Updated: Sep 1, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.1K

Interstitial lung diseases.

Marlies Wijsenbeek1, Atsushi Suzuki2, Toby M Maher3

  • 1Center for Interstitial Lung Diseases and Sarcoidosis, Department of Respiratory Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.

Lancet (London, England)
|August 14, 2022
PubMed
Summary
This summary is machine-generated.

Interstitial lung diseases (ILDs) encompass over 200 conditions, often causing breathlessness and reduced quality of life. Recent advances offer new treatments for progressive pulmonary fibrosis and related conditions.

More Related Videos

Author Spotlight: Investigating the Key Factors of Obliterative Bronchiolitis After Lung Transplantation
06:15

Author Spotlight: Investigating the Key Factors of Obliterative Bronchiolitis After Lung Transplantation

Published on: November 10, 2023

986
A Standardized Method for Measuring Internal Lung Surface Area via Mouse Pneumonectomy and Prosthesis Implantation
08:46

A Standardized Method for Measuring Internal Lung Surface Area via Mouse Pneumonectomy and Prosthesis Implantation

Published on: July 26, 2017

13.4K

Related Experiment Videos

Last Updated: Sep 1, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.1K
Author Spotlight: Investigating the Key Factors of Obliterative Bronchiolitis After Lung Transplantation
06:15

Author Spotlight: Investigating the Key Factors of Obliterative Bronchiolitis After Lung Transplantation

Published on: November 10, 2023

986
A Standardized Method for Measuring Internal Lung Surface Area via Mouse Pneumonectomy and Prosthesis Implantation
08:46

A Standardized Method for Measuring Internal Lung Surface Area via Mouse Pneumonectomy and Prosthesis Implantation

Published on: July 26, 2017

13.4K

Area of Science:

  • Pulmonology
  • Rheumatology
  • Rare Diseases

Background:

  • Over 200 interstitial lung diseases (ILDs) are recognized, varying from rare to common.
  • Most ILDs involve inflammation or fibrosis, impairing gas exchange and leading to symptoms like breathlessness and reduced quality of life.
  • Outcomes for ILDs are highly variable, with some patients experiencing spontaneous improvement while others face progressive pulmonary fibrosis, respiratory failure, and death.

Purpose of the Study:

  • To provide an update on the epidemiology, pathogenesis, presentation, diagnosis, disease course, and management of common interstitial lung diseases.
  • To highlight recent advances in ILD treatment, particularly for progressive pulmonary fibrosis.
  • To summarize practice-changing guidelines and discuss future directions in ILD research and care.

Main Methods:

  • Review of current literature and clinical practice guidelines.
  • Synthesis of recent epidemiological data and insights into disease pathogenesis.
  • Analysis of therapeutic advancements and treatment strategies for various ILDs.

Main Results:

  • Significant progress has been made in the last three years, with new drug approvals for systemic sclerosis-associated ILD, ILD-associated pulmonary hypertension, and progressive pulmonary fibrosis.
  • A shift in the classification and treatment of progressive fibrotic ILDs is evident, guided by updated guidelines.
  • The seminar covers frequently encountered ILDs, offering a comprehensive overview of their clinical aspects.

Conclusions:

  • Recent therapeutic developments offer new hope for patients with interstitial lung diseases, especially those with progressive pulmonary fibrosis.
  • Updated guidelines are transforming the management of ILDs, emphasizing a more personalized and evidence-based approach.
  • Ongoing research is crucial to address remaining controversies and uncertainties in the field of ILD.